GGrantIndex
← Leaderboards

Fredric Manfredsson

State University Of Ny,Binghamton

$6,348,589
Attributed
$11,988,028
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY201625
$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,988,028 · 10

By mechanism

R01$9,053,738 · 3
R21$1,327,412 · 3
R61$1,009,212 · 1
R56$577,666 · 1
R13$20,000 · 2

Most similar at State University Of Ny,Binghamton

Same institution · by research overlap

Others in their field

Top investigators on “Neurons

Research focus

NeuronsParkinson DiseasePreventMediatingRattusBrainPhenotypeLinkCorpus Striatum StructureLevodopaMolecularRecombinant Adeno-Associated Virus (Raav)Gene TherapyGeneticDoseReportingPathologyDependovirusBehaviorPharmaceutical PreparationsDopamineMotorQuality Of LifeParkinsonian Disorders

Grant awards (28)

A novel gene therapy approach to reduce neurotoxicity in Parkinson's disease$1,009,212
R61 · FY2025 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$643,792
R01 · FY2025 · NS
Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced Dyskinesia$605,836
R01 · FY2025 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$952,368
R01 · FY2024 · NS
Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced Dyskinesia$593,907
R01 · FY2024 · NS
Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced Dyskinesia$651,165
R01 · FY2023 · NS
Interrogating maladaptive serotonin raphe-striatal plasticity in L-DOPA-induced dyskinesia$689,984
R01 · FY2022 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$468,320
R01 · FY2022 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$568,415
R01 · FY2021 · NS
Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon$367,016
R01 · FY2021 · DK · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$590,058
R01 · FY2020 · NS
Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon$367,016
R01 · FY2020 · DK · contact PI
Development of novel viral vectors to study and treat neuroinflammation$215,920
R21 · FY2020 · AG · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$561,645
R01 · FY2019 · NS
Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon$348,750
R01 · FY2019 · DK · contact PI
Development of novel viral vectors to study and treat neuroinflammation$244,201
R21 · FY2019 · AG · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$598,419
R01 · FY2018 · NS
Gut-Brain Axis in Alzheimer's Disease$349,547
R01 · FY2018 · DK · contact PI
Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon$348,750
R01 · FY2018 · DK · contact PI
American Society for Neural Therapy and Repair 2018 Meeting$10,000
R13 · FY2018 · NS · contact PI
Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon$348,750
R01 · FY2017 · DK · contact PI
Striatal Nurr1 activity facilitates the dyskinetic state: A novel therapeutic target$194,275
R21 · FY2017 · NS · contact PI
Alpha-synuclein is crucial for neuronal function and survival-Characterization of a novel conditional alpha-synuclein knockout mouse model$178,158
R21 · FY2017 · NS · contact PI
Alpha-synuclein is crucial for neuronal function and survival-Characterization of a novel conditional alpha-synuclein knockout mouse model$15,592
R21 · FY2017 · NS · contact PI
American Society for Neural Therapy and Repair$10,000
R13 · FY2017 · NS · contact PI
Viral Vector Transduction Deficiencies in the Aged Nigrostriatal System$577,666
R56 · FY2016 · AG
Striatal Nurr1 activity facilitates the dyskinetic state: A novel therapeutic target$246,766
R21 · FY2016 · NS · contact PI
Alpha-synuclein is crucial for neuronal function and survival-Characterization of a novel conditional alpha-synuclein knockout mouse model$232,500
R21 · FY2016 · NS · contact PI